

Case report

Open Access

Solitary intrathyroidal metastasis of renal clear cell carcinoma in a toxic substernal multinodular goiter

Gianlorenzo Dionigi*¹, Silvia Uccella², Myriam Gandolfo³, Adriana Lai³,
Valentina Bertocchi¹, Francesca Rovera¹ and Maria Laura Tanda³

Address: ¹Department of Surgical Sciences, University of Insubria, Varese, Italy, ²Human Morphology, University of Insubria, Varese, Italy and ³Clinical Medicine, University of Insubria, Varese, Italy

Email: Gianlorenzo Dionigi* - gianlorenzo.dionigi@uninsubria.it; Silvia Uccella - silvia.uccella@uninsubria.it;
Myriam Gandolfo - myriam.gandolfo@uninsubria.it; Adriana Lai - adriana.lai@uninsubria.it;
Valentina Bertocchi - valentina.bertocchi@uninsubria.it; Francesca Rovera - francesca.rovera@uninsubria.it;
Maria Laura Tanda - marialaura.tanda@uninsubria.it

* Corresponding author

Published: 24 October 2008

Received: 29 May 2008

Thyroid Research 2008, 1:6 doi:10.1186/1756-6614-1-6

Accepted: 24 October 2008

This article is available from: <http://www.thyroidresearchjournal.com/content/1/1/6>

© 2008 Dionigi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction: Thyroid gland is a rare site of clinically detectable tumor metastasis.

Case report: A 71-year-old woman was referred to our department for an evaluation of toxic multinodular substernal goiter. She had a history of renal clear cell carcinoma of the left kidney, which had been resected 2 years previously. US confirmed the multinodular goiter. Total thyroidectomy with neuromonitoring was performed on March 2008. A histological examination revealed a solitary metastasis of a clear cell renal cancer in a diffuse multinodular goiter. No distant metastases are detected.

Conclusion: Although uncommon, it is important for the endocrine surgeon and endocrine oncologist to be able to recognize and differentiate intrathyroid metastases from more primary common thyroid neoplasms. The diagnosis can be suspected if the patient has a thyroid tumor and a past history of extrathyroid cancer. These tumors, on the whole, tend to behave more aggressively and, in most cases, the use of multimodality therapy is recommended.

Introduction

Thyroid cancer refers to any kind of malignant tumors of the thyroid gland [1,2]. Thyroid cancers can be classified according to their pathological characteristics and origin in primary and secondary (i.e. metastases) [1,2].

The four main types of primary thyroid cancer are papillary, follicular, medullary, and anaplastic thyroid cancer [3]. Papillary and follicular carcinoma are the most common form of differentiated follicular cell-derived carcinomas and comprises 90–95% of all newly diagnosed

thyroid cancers [3]. Medullary thyroid cancer is a rare and aggressive type of cancer deriving from the parafollicular cells and accounting for 5% of all thyroid carcinomas [4]. Other rare types of primary thyroid malignant tumors are squamous cell carcinoma, mucoepidermoid carcinoma, sclerosing mucoepidermoid with eosinophilia, teratomas, mucinous carcinoma, spindle cell tumor, lymphomas and carcinoma showing thymus-like element [5-13]. The thyroid gland is a rare site of clinically detectable tumor metastasis: a palpable thyroid tumor is usually assumed to be a primary thyroid tumor [14].

This report describes herein a patient with solitary metastasis to the thyroid, who had undergone a left nephrectomy for renal clear cell carcinoma 2 years previously. Unique pathological figures are presented.

Case report

A 71-year-old woman underwent nephrectomy of the right kidney for renal clear cell carcinoma on September 26, 2006. The tumor measured 28 mm in size and was localized in the upper pole of the right kidney. The tumor had been incidentally demonstrated on routine ultrasonography (US). Preoperative whole body CT-scan was negative for local and distant metastases. In the final histological examination, the tumor extended into a renal vein, regional nodes could not be assessed (pT3b, pNX, G2). The surgical margin was free of the tumor. Her postoperative course was uneventful. Neither postoperative adjuvant chemotherapy nor interferon was given.

In September 2006, she was also referred to the Department of Clinical Medicine, Division of Endocrinology, for an evaluation of toxic substernal goiter with chronic thyroiditis. She had no complaints that could be related to thyroid dysfunction, nor stridor, hoarseness, dysphagia. A multinodular goiter was noticed at palpation. The patient underwent antithyroid medication with methimazole.

On January 2008 the patient underwent new endocrine consultation. Her general health condition was excellent. She was euthyroid and all laboratory data were normal. US demonstrated diffuse, bilateral and well-demarcated micro and micronodules both normoechoic and hypoechoic containing high-echo spots representing small calcifications measuring $13 \times 14 \times 18$ mm, $14 \times 17 \times 17$ mm, $16 \times 16 \times 14$ mm and $16 \times 22 \times 20$ mm. She underwent a total thyroidectomy with intraoperative neuromonitoring (NIM-Response 2.0 System, Medtronic Xomed, Jacksonville, Florida).

Five mm-thick sections were stained with hematoxylin-eosin (H&E) for histopathologic examination. Additional 3 mm-thick sections, collected on positively charged slides (SuperFrost®Plus, Menzel GmbH & Co KG, Braunschweig) were used for immunohistochemical analysis. The immunostainings for CD10 (clone 56 CG) and TTF-1 (Thyroid Transcription Factor, clone 8G7G3/1) were performed with an automated immunostainer (Benchmark XT, Ventana Medical Systems).

At macroscopic examination the thyroid was enlarged, with a distorted shape, the left lobe being larger than the right one. On cross section, the gland was occupied by multiple nodules, some of which were partially cystic and showed areas of calcification and haemorrhage. A histological diagnosis of nodular hyperplasia was formulated.

In addition, as shown in figure 1, nodule with a golden yellow cut surface, measuring 1 cm in its larger dimension, was observed in the left lobe. Microscopically, the nodule was surrounded by a complete fibrous capsule and showed a proliferation of large cells with abundant optically clear cytoplasm and sharply outlined boundaries, arranged in nests and cords. The nuclei showed mild to moderate atypia and single or multiple nucleoli were visible at $\times 400$ magnification. The neoplastic cells were strongly immunoreactive for CD10, which is commonly expressed in renal cell carcinomas. By contrast, TTF-1 was completely negative, and this ruled out a primary tumour of the thyroid. Based on these findings and on the similarity of this proliferation with the renal cell neoplasm diagnosed in the kidney two years before, a diagnosis of an intrathyroid metastasis of renal cell carcinoma, grade II, was made.

Her postoperative course was uneventful.

Postoperative bone scintigraphy and computer tomography also revealed the absence of any other metastases. She has been doing well without any evidence of recurrence for 5 months after thyroidectomy.

Discussion

The prevalence of intrathyroid metastases of nonthyroid origin ranges from 1.9% to 25% [15-24]. Mortensen et al. account 4% of patients with metastatic neoplasm with secondary tumors to the thyroid gland [25]. Silverberg meticulously examined the gland and found an incidence of 25% in patients dying from disseminated malignant tumor of other primary [26].

Primary carcinomas of the lung, kidney, breast, stomach are the most common tumors metastasizing to the thyroid [15-24]. Carcinomas of the colon, gynecologic tumors, oral cavity, esophagus, neuroendocrine cancers, and sarcomas have been rarely published only in case reports or small series [15-24]. In the study of Shimaoka et al., metastases to the thyroid gland occurred in 39% of melanoma patients, 21% of breast cancer patients, 12% renal cancer, 10% of lung cancer and 10% of patients with primary head and neck tumors [27]. Chen et al. reported ten patients with thyroid metastases and 50% of these patients had metastases from renal cell carcinoma [28]. Thus, renal cell carcinoma is by far the most common source of clinically relevant metastases to the thyroid gland [28].

However, considering that the reported metastases of autopsy cases included nonclinically metastasis (i.e. occult cancer or widespread cancer at the time of death), a better estimate of the incidence of clinically apparent metastases to the thyroid has been shown in clinical stud-




Figure 1
Histopathology of renal cell carcinoma metastasis in the thyroid: capsulated intrathyroidal nodule (A) composed of nests and cords of large clear cells (B) with abundant optically empty cytoplasm, sharply outlined boundaries and moderately atypical nuclei (C). The clear cells are CD10-immunoreactive (D). (H&E, $\times 10$, $\times 100$ and $\times 400$; avidin-biotin-peroxidase, $\times 400$).

ies. The incidence of clinically significant metastases appears to be lower than the incidence found in autopsy. According to Shimaoka, the thyroid metastases were rarely clinically apparent in only 5% to 10% of the patients [27]. Wychulis et al. described that only 10 of 20262 patients, who had undergone thyroidectomy at the Mayo Clinic, had symptomatic metastatic involvement of the thyroid gland [29].

In clinical practice, in a patient with a diffuse and bilateral multinodular goiter, a correct diagnosis is difficult, since there are no specific findings of metastatic thyroid tumor on ultrasonography or computer tomography scan investigations. Elliott and Frantz found 44 reported cases of metastatic carcinoma that had been misidentified as primary thyroid cancer [14].

Therefore, a correct diagnosis of metastatic thyroid tumors requires a careful consideration of patients with a history of cancer. This information immediately stratifies a patient into a high risk category.

Moreover, the presentation of a thyroid nodule years after the treatment of a primary cancer often poses a diagnostic dilemma. Often there is a latency period lasting years between the diagnosis of the primary cancer and the appearance of the thyroid mass [30]. Latent intervals of up to 20 years have also been reported [30]. This finding is especially true for renal primary tumors [30]. In these cases with a long interval between the detection of the primary tumor and the development of the thyroid metastasis, the difficulty in making a correct diagnosis could increase as well.

On the other hand, there have been several reports on metastasis to the thyroid, which appeared prior to the primary tumor being detected [31].

Fine needle aspiration cytology (FNA) can allow for the preoperative diagnosis of a secondary tumor, thus changing the preoperative work-up of such patient [32-34]. Once the diagnosis of metastatic disease has been confirmed on FNA, the patient should undergo a metastatic work-up to rule out other distant metastases [32-34].

Finally, if technically feasible, thyroidectomy can be effective for local control [35]. Surgical resection is regarded as the best treatment for a metastatic thyroid tumor, especially if the primary carcinoma appears to be controlled and there is no evidence of metastasis elsewhere [36]. Moreover, considering the size and rapid growth of the thyroid tumor, even if the patient had already had other metastatic lesions, thyroidectomy would still be required in order to relieve tracheal compression. This is especially true for tumors that present years after the treatment of the primary cancer.

Survival time after diagnosis of the thyroid metastases is determined by the biology of the primary disease [32-36]. Our patient has no evidence of recurrence 5 months after thyroid surgery. Authors have demonstrated that for isolated thyroid metastases, thyroidectomy has prolonged survival. Chen et al. reported that 60% of the patients with solitary thyroid metastasis were still alive after a thyroidectomy during a median follow-up period of 5.2 years [28].

After surgical management, the administration of systemic therapy is recommended [35].

Authors' contributions

GD: acquisition of data. GD, FR, SU: study conception and design. MG, GD, MLT: analysis and interpretation of data, drafting of manuscript. GD, VB, AL: Critical revision and supervision. The manuscript has been seen and approved by all authors.

Competing interests

The authors declare that they have no competing interests.

Consent

A written consent of the patient was obtained for publication of this report.

References

1. Shaha AR: **TNM classification of thyroid carcinoma.** *World J Surg* 2007, **31(5)**:879-87.
2. Döbert N, Menzel C, Oeschger S, Grünwald F: **Differentiated thyroid carcinoma: the new UICC 6th edition TNM classification system in a retrospective analysis of 169 patients.** *Thyroid* 2004, **14(1)**:65-70.
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, the European Thyroid Cancer Taskforce: **European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.** *Eur J Endocrinol* 2006, **154**:787-803.
4. Dionigi G, Tanda ML, Piantanida E: **Medullary thyroid carcinoma: surgical treatment advances.** *Curr Opin Otolaryngol Head Neck Surg* 2008, **16(2)**:158-62.
5. Samaan NA, Ordoñez NG: **Uncommon types of thyroid cancer.** *Endocrinol Metab Clin North Am* **19(3)**:637-48. 1990 Mar 1
6. Makay O, Kaya T, Ertan Y, Icoz G, Akyildiz M, Yilmaz M, Tuncyurek M, Yetkin E: **Primary Squamous Cell Carcinoma of the Thyroid: Report of Three Cases.** *Endocr J* 2008 in press.
7. Minagawa A, Iitaka M, Suzuki M, Yasuda S, Kameyama K, Shimada S, Kitahama S, Wada S, Katayama S: **A case of primary mucoepidermoid carcinoma of the thyroid: molecular evidence of its origin.** *Clin Endocrinol (Oxf)* 2002, **57(4)**:551-6.
8. Geisinger KR, Steffee CH, McGee RS, Woodruff RD, Buss DH: **The cytomorphologic features of sclerosing mucoepidermoid carcinoma of the thyroid gland with eosinophilia.** *Am J Clin Pathol* 1998, **109(3)**:294-301.
9. Thompson LD, Rosai J, Heffess CS: **Primary thyroid teratomas: a clinicopathologic study of 30 cases.** *Cancer* 2000, **88(5)**:1149-58.
10. Kondo T, Kato K, Nakazawa T, Miyata K, Murata S, Katoh R: **Mucinous carcinoma (poorly differentiated carcinoma with extensive extracellular mucin deposition) of the thyroid: a case report with immunohistochemical studies.** *Hum Pathol* 2005, **36(6)**:698-701.
11. Haberal AN, Aydin H, Turan E, Demirhan B: **Unusual spindle cell tumor of thyroid (SETTLE).** *Thyroid* 2008, **18(1)**:85-7.
12. Kossev P, Livolsi V: **Lymphoid lesions of the thyroid: review in light of the revised European-American lymphoma classification and upcoming World Health Organization classification.** *Thyroid* 1999, **9(12)**:1273-80.
13. Chow SM, Chan JK, Tse LL, Tang DL, Ho CM, Law SC: **Carcinoma showing thymus-like element (CASTLE) of thyroid: combined modality treatment in 3 patients with locally advanced disease.** *Eur J Surg Oncol* 2007, **33(1)**:83-5.
14. Elliott RH, Frantz VK: **Metastatic carcinoma masquerading as primary thyroid cancer: a report of authors' 14 cases.** *Ann Surg* 1960, **151**:551-561.
15. Ivy HK: **Cancer metastatic to the thyroid: a diagnostic problem.** *Mayo Clin Proc* 1984, **59**:856-859.
16. Hull OH: **Critical analysis of two hundred twenty-one thyroid glands; study of thyroid glands obtained at necropsy in Colorado.** *AMA Arch Pathol* 1955, **59(3)**:291-311.
17. Lin JD, Weng HF, Ho YS: **Clinical and pathological characteristics of secondary thyroid cancer.** *Thyroid* 1998, **8(2)**:149-53.
18. Akimaru K, Onda M, Tajiri T, Shimanuki K, Iwama H, Furukawa K, Sugiyama Y: **Colonic adenocarcinoma metastatic to the thyroid: report of a case.** *Surg Today* 2002, **32(2)**:151-4.
19. Rosen IB, Walfish PG, Bain J, Bedard YC: **Secondary malignancy of the thyroid gland and its management.** *Ann Surg Oncol* 1995, **2(3)**:252-6.
20. Cichoń S, Anielski R, Konturek A, Barczyński M, Cichoń W: **Metastases to the thyroid gland: seventeen cases operated on in a single clinical center.** *Langenbecks Arch Surg* 2006, **391(6)**:581-7.
21. Lam KY, Lo CY: **Metastatic tumors of the thyroid gland: a study of 79 cases in Chinese patients.** *Arch Pathol Lab Med* 1998, **122(1)**:37-41.
22. Nakhjavani MK, Gharib H, Goellner JR, van Heerden JA: **Metastasis to the thyroid gland. A report of 43 cases.** *Cancer* **79(3)**:574-8.
23. Wood K, Vini L, Harmer C: **Metastases to the thyroid gland: the Royal Marsden experience.** *Eur J Surg Oncol* 2004, **30(6)**:583-8.
24. Czech JM, Lichtor TR, Carney JA, van Heerden JA: **Neoplasms metastatic to the thyroid gland.** *Surg Gynecol Obstet* 1982, **155(4)**:503-5.
25. Mortensen J, Woolner LB, Bennett WA: **Secondary malignant tumors of the thyroid gland.** *Cancer* 1956, **9(2)**:306-9.
26. Silverberg SG, Vidone RA: **Metastatic tumors in the thyroid.** *Pacif Med Surg* 1966, **74**:175-180.
27. Shimaoka K, Sokal JE, Pickren JW: **Metastatic neoplasms in the thyroid gland. Pathological and clinical findings.** *Cancer* 1962, **15**:557-565.

28. Chen H, Nicol TL, Udelsman R: **Clinically significant, isolated metastatic disease to the thyroid gland.** *World J Surg* 1999, **23**:177-181.
29. Wychulis AR, Beahrs OH, Woolner LB: **Metastasis of carcinoma to the thyroid gland.** *Ann Surg* 1964, **160**:169-177.
30. Shima H, Mori H, Takahashi M, Nakamura S, Miura K, Tarao M: **A case of renal cell carcinoma solitarily metastasized to thyroid 20 years after the resection of primary tumor.** *Pathol Res Pract* 1985, **179**:666-670.
31. Fabbro SD, Monari G, Barbazza R: **A thyroid metastasis revealing an occult renal clear-cell carcinoma.** *Tumori* 1987, **73**:187-190.
32. Heffess CS, Wenig BM, Thompson LD: **Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases.** *Cancer* **95**(9):1869-78.
33. Friberg S, Kinnman J: **Renal adenocarcinoma with metastases to the thyroid gland.** *Acta Otolaryngol* 1969, **67**:552-562.
34. Gault EW, Leung THW, Thomas DP: **Clear cell renal carcinoma masquerading as thyroid enlargement.** *J Pathol* 1974, **113**:21-25.
35. Green LK, Ro JY, Mackay B, Ayala AG, Luna MA: **Renal cell carcinoma metastatic to the thyroid.** *Cancer* 1989, **63**:1810-1815.
36. Saitoh H: **Distant metastasis of renal adenocarcinoma.** *Cancer* 1981, **48**:1487-1491.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

